Author's posts
The Scientologist Billionaire Trying To Make A New Antibiotic
Bob Duggan could easily have called it a career in 2015, after he sold Pharma- cyclics, his cancer-drug biotech, to AbbVie.
GoodRx IPO Shows Low Drug Prices Can Still Mean Big Money
The drug pricing company was valued above $19 billion on its first day on the market.
This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi
In order to find the next penicillin, Menlo Park-based startup Hexagon Bio uses an AI platform to sequence the genomes of fungi.
Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug
The drug, sumifilam, targets a new protein in Alzheimer’s disease called Filamen A.
International Scientists Skeptical Of Data In Russian Covid-19 Vaccine Trial
The scientists imply that some of the data may have been falsified and ask for access to the original data.
Recursion Pharmaceuticals Raises $239 Million And Partners With Bayer For AI Drug Discovery
The Utah-based biotech company’s agreement with Bayer is potentially worth over $1 billion.
Why ‘T Cell Immunity’ Won’t End The Coronavirus Pandemic
On social media, ‘T cell immunity’ is being invoked to imply the Covid-19 pandemic might end this Fall. The science suggests otherwise.
Gilead Testing Inhaled Form Of Remdesivir That Could Be Used To Treat Covid-19 Outside Hospital
The inhaled form of remdesivir, one of the only medications that’s shown any promise in treating Covid-19, could be given to patients outside of the hospital.
Exclusive: Telemedicine Company Doctor On Demand Raises $75 Million To Expand During The Covid-19 Pandemic
While many businesses are suffering during the recession caused by the coronavirus pandemic, telemedicine companies, including Doctor on Demand, are doing better than ever.
Regeneron’s Billionaire Cofounder Criticized After ‘All Lives Matter’ Graduation Speech
Speaking at a high school graduation in Yorktown, NY, Regeneron cofounder and Chief Scientific Officer Dr. George Yancopoulos said that police are “scapegoats” for larger race issues.
